Skip to Content

    Alzheimer's Association Statement Regarding Washington Post Article on Pfizer/Amgen Enbrel Decision in Alzheimer’s

    Alzheimer's Association Statement Regarding Washington Post Article on Pfizer/Amgen Enbrel Decision in Alzheimer’s

    Chief Science Officer: Any Promising Science Should Be Pursued or Shared With Research Community

    CHICAGO, June 5, 2019 — “Any science that has promise for Alzheimer’s disease and other dementias and is not genuinely pursued, or shared with the research community, does a disservice to the millions of individuals facing the disease today and in the future. Alzheimer's is a personally devastating and fatal disease, the sixth leading cause of death in the United States, with the number of people impacted by the disease increasing daily. No stone should be left unturned. The expectation of the Alzheimer’s Association and our millions of constituents is that every possible path is pursued thoroughly and aggressively with people living with the disease as a priority.”

    — Maria C. Carrillo, Ph.D., chief science officer, Alzheimer’s Association
     

    About the Alzheimer's Association

    The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.